Skip to main content

68th Annual Scientific Meeting Main banner

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Presentation Icons

Red Recording

Sig Meeting

Jeremias Antinew, MD photo

Jeremias Antinew, MD

Clinical Development Medical Senior Director
Pfizer Inc.

Poster(s):

(T 22) Rimegepant for the Preventive Treatment of Migraine: A Phase 3, Randomized, Double-blind, Placebo-controlled Study in Adults from China
(T 32) A phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of zavegepant for the acute treatment of migraine in Asian adults